Triple-negative breast cancer (TNBC) accounting for approximately 15% of invasive breast cancers, is the most aggressive subtype, which has the characteristic of loss of expression of estrogen receptor (ER) and progesterone receptor (PR) and does not have amplification of the epidermal growth factor receptor 2 (ERBB2). This evidence concerns the gene ESR1 and triple-negative breast carcinoma.